Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced long-term follow-up data from its pivotal Phase 2 PACE clinical trial of Iclusig® (ponatinib), its approved BCR-ABL inhibitor, in …
With more than 30,000 attendees, the American Society of Clinical Oncology (ASCO) annual meeting is the largest cancer conference in the world. As …
Adamis Pharmaceuticals Corp (NASDAQ:ADMP) is plummeting nearly 50% down to $4.55 after the FDA rejected the company’s New Drug Application for the second …
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced updated clinical data on brigatinib, its investigational anaplastic lymphoma kinase (ALK) inhibitor, from the pivotal ALTA trial in patients …
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that it has completed the sale of its European operations to Incyte Corporation and entered into the previously announced …
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced initiation of the Phase 1/2 clinical trial of AP32788, an investigational tyrosine kinase inhibitor (TKI) designed as a targeted …
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) released positive data this week and Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) had an investor event, leading analysts to share updated …
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced the appointment of Jennifer L.
Analysts weighed in on biopharmaceutical stocks Horizon Pharma PLC (NASDAQ:HZNP) and Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA).
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that negotiations with the Economic Committee on Health Care Products inFrance regarding pricing and reimbursement for Iclusig® (ponatinib) have …
